|
**Overview**: Filaria Antibodies Panel**Introduction**: The Filaria Antibodies Panel is a diagnostic tool designed to screen for filarial infection using serum samples. In India, lymphatic filariasis (caused by Wuchereria bancrofti) affects ~20 million people (endemic in 17 states), with chronic lymphedema, hydrocele, and elephantiasis as major sequelae. IgG/IgM indicate exposure/infection. High morbidity from underdiagnosis in rural endemic areas, limited serology access, delayed DEC or mass drug administration leading to disability. Per microbiology practices aligned with ICMR and NVBDCP guidelines, the test employs immunoassay for filaria IgG/IgM over 1-2 days with high sensitivity/specificity, valuable for active case detection and surveillance. This diagnostic falls under parasitic screening and targets patients with lymphedema, fever, or endemic exposure, addressing accurate detection to guide DEC therapy and morbidity management. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing filariasis burden. Its serum-based approach ensures reliable antibody detection.**Other Names**: Filaria Ab Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Antibody testing adjunct to antigen; in India, used in elimination programs.**Purpose**: The test screens for 2 parameters including filaria IgG to guide infection assessment, detect exposure, inform therapy.**Test Parameters**: 1. Filaria IgG, 2. Filaria IgM.**Pretest Condition**: No fasting required; patients should report limb swelling, fever, or endemic exposure.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on swelling, nocturnal fever, travel to endemic areas.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated filariasis including disability, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or cross-reactivity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibodies indicate filarial exposure/infection, necessitating specialist input. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Infectious disease specialists should be consulted for management.**Additional Supporting Tests**: Antigen test, night blood smear for confirmation.**Test Limitations**: Cannot distinguish active vs past infection; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, Filariasis Studies India 2023. |
